Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) Stock Analysis

BSE: 500676 | NSE: GSKCONS | Consumer Food | Mid Cap

BSE Share Price 15-Apr-2020 18:01
9696.40 0.00 (0.00%)

DeciZen - Make an Informed Decision on Glaxo.Cons. Health

M-Cap below 100cr DeciZen not available

Glaxo.Cons. Health Price Chart

P/E Ratio ( SA) :
39.13
Market Cap :
45,225.1 Cr.
52-wk low :
9,696.4
52-wk high :
10,845.8
Bole Toh?

1. Is a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) is a good quality company.

2. Is undervalued or overvalued?

The key valuation ratios of Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Glaxo.Cons. Health:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
ROCE % 28.3%32.3%33.7%34.7%42.3%29.8%27.7%22.1%21.1%25.8%-
Value Creation Index 1.11.41.51.62.11.71.51.00.91.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,9222,3062,7653,1873,8954,3084,1363,9914,3174,7824,984
YoY Gr. Rt. %-20%19.9%15.3%22.2%10.6%-4%-3.5%8.2%10.8%-
Adj EPS 55.471.283.8102.9127.4138.9161.7155.5165.3232.3274.8
YoY Gr. Rt. %-28.5%17.7%22.7%23.9%9%16.4%-3.8%6.3%40.6%-
BVPS (₹) 215.2228.3272.1323.6344.9502.4665.5742.5828.7973.71,055.4
Adj Net Profit 2332993524335365846806546959771,156
Cash Flow from Ops. 400326391554516611573603723671-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.7%4.2%5%10.8%
Adj EPS 17.3%12.8%12.8%40.6%
BVPS 18.323.113.517.5
Share Price 6.3% 8.1% -3.4% -9.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
Return on Equity % 2832.133.534.542.229.827.722.12125.827.1
Op. Profit Mgn % 16.316.418.2181817.220.32120.523.925.4
Net Profit Mgn % 12.11312.813.613.813.616.416.416.120.423.2
Debt to Equity 0000000000-
Working Cap Days 1781571701181152232502943243320
Cash Conv. Cycle 3-12-12-14-14-18-33-43-53-500

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)

Standalone Consolidated
TTM EPS (₹) 274.8 -
TTM Sales (₹ Cr.) 4,984 -
BVPS (₹.) 1,055.4 -
Reserves (₹ Cr.) 4,396 -
P/BV 10.19 -
PE 39.13 -
From the Market
52 Week Low / High (₹) 9696.40 / 10845.75
All Time Low / High (₹) 93.75 / 11290.00
Market Cap (₹ Cr.) 45,225
Equity (₹ Cr.) 42.1
Face Value (₹) 10
Industry PE 59.7

Management X-Ray of Glaxo.Cons. Health :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Glaxo.Cons. Health

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Glaxo.Cons. Health on 15-Apr-2020 18:01 is : 9,696.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Apr-2020 18:01 the market cap of Glaxo.Cons. Health stood at ₹ 45,225.1.
The latest PE ratio of Glaxo.Cons. Health as of 15-Apr-2020 18:01 is 39.13.
The latest PB ratio of Glaxo.Cons. Health as of 15-Apr-2020 18:01 is 10.19
The 52-week high of Glaxo.Cons. Health is ₹ 10,845.8 and the 52-week low is ₹ 9,696.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Glaxo.Cons. Health is ₹ 4,984 ( Cr.) .

About Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)

Glaxosmithkline Consumer Healthcare’s (GCH) core business is manufacturing of health drinks under the brand Horlicks. The history of the company goes way back in 1950s when bottled Horlicks was imported from England. But in the year 1955 due to change in import policy, import of Horlicks was stopped.

During 1956-57 a team of Horlicks visited India to explore possibilities for setting up a plant in India. For this the company approached Maharaja of Nabha, Pratap Singh in Punjab. Later in October 1958 with the support of Maharaja, Hindustan Milkfood Manufacturer (HMML) was established to produce Horlicks.

In the year 1969 Beecham plc acquired Horlicks England, which led the company to become major shareholder in HMML. In 1979 Beecham India was merged with Hindustan Milkfood Manufacturer. Later Beecham plc, UK got merged with SmithKline USA.

In January 2000 the name was changed to Glaxosmithkline Consumer Healthcare.

It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.

GCH has manufacturing plants located at Punjab, Andhra Pradesh, Haryana, Hyderabad, Chennai, Guwahati, Ghaziabad, Bangalore and Gurgaon.

Glaxosmithkline Consumer Healthcare has entered into an agreement with Laclede to purchase its dry mouth brand Biotene for $170 million.

In 2011 GSk has launched Sensodyne in an attempt to enter the Indian tooth paste market. "

Products

Nutritional drinks- Under this it manufactures and markets wide range of health drinks. Besides Horlicks, it has created brands like, Boost, Maltova and Viva. Apart from youth, it also caters to other consumers like mothers with Mother’s Horlicks and Horlicks Lite for diabetic consumers.

OTC Products- It promotes and distributes over the counter drugs like pain relief balm -- Iodex, pain relief tablet and syrup -- Crocin and drug for acidity problems -- Eno.

The company’s nutritional food services division has also developed vending of Boost and Horlicks. Around 500 vending machine have been placed in corporates, schools and hospitals.

Award and Recognition

It manufacturing plants have received various certification for its quality and health and safety systems such as OHSAS 18001, ISO 9001:2000 and ISO 14001:2004 by DNV and SA8000.

The company’s Sonepat factory has won the prestigious “National Energy Conservation Award – 2007” from the President of India in the Food Processing Sector.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now